{
    "2021-12-06": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Where Do Hedge Funds Stand On AbbVie Inc (ABBV)?",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "AbbVie",
                        "Investment"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-02",
                "original_text": "AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "Warnings",
                        "Rinvoq"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-03",
                "original_text": "Upadacitinib (RINVOQÂ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "RINVOQ",
                        "Phase 3",
                        "Crohn's Disease",
                        "Endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}